NVCR

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. NovoCure (NVCR) drew fresh investor attention after raising its 2026 net revenue guidance to a range of US$710 million to US$725 million, following a quarter of record sales and active patient growth. See our latest analysis for NovoCure. The recent guidance upgrade and record quarter come after a sharp swing in sentiment around NovoCure, with the stock gaining 41.54% on a 3 month share price return and 46.59% on a 1 year total shareholder return. However, longer term total shareholder returns over 3 and 5 years remain significantly negative, indicating momentum is still rebuilding after a prolonged drawdown. If NovoCure's recent move has you looking at other oncology and medical technology ideas, it could be worth scanning for emerging healthcare AI opportunities through the 39 healthcare AI stocks. Bulls see NovoCure’s rebound, guidance lift and active patient growth as the start of a reset, while bears point to ongoing losses and past drawdowns. Which side does the current valuation actually support? The most followed narrative on NovoCure currently pegs fair value at $26.07, well above the last close of $17.65, and ties that gap to specific growth and margin assumptions. Read the complete narrative. Read the complete narrative. Want to see what sits behind that fair value for NovoCure? The narrative leans on accelerating revenue, a sharp swing in profit margins, and a future earnings multiple more often linked to faster growing peers. Curious which assumption does the most work in that model and how sensitive the outcome is to small changes in growth or profitability? Result: Fair Value of $26.07 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, NovoCure’s story can change quickly if prescription growth in key launches stalls or if broad reimbursement fails to materialise, which could keep margins under pressure. Find out about the key risks to this NovoCure narrative. If the mixed sentiment around NovoCure has you unsure, this is the moment to look at the numbers yourself and move quickly. Balance the optimism with the concerns by weighing up the 2 key rewards and 2 important warning signs. If NovoCure has reignited your interest in the market, do not stop here. Use the Simply Wall St Screener to quickly spot other opportunities that fit your style. Target resilient payouts and income stability by scanning companies in the 9 dividend fortresses. Hunt for quality at a reasonable price by reviewing the 49 high quality undervalued stocks that meet your return and risk preferences. Prioritise capital protection by focusing on companies in the 81 resilient stocks with low risk scores that score well on resilience and financial strength. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NVCR. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achieved the strongest commercial quarter to date with record net revenues and active patients, driven by 11% year-over-year growth in Optune Gio. Attributed U.S. Optune Gio growth of 8% to the realization of long-term strategic and structural changes in domestic commercial operations. Successfully initiated the Optune Pax launch in the U.S., securing 418 prescriptions and 285 patients on therapy within the first full quarter. Observed strong early adoption of Optune Lua in Japan following national reimbursement, noting that Japanese clinical practice patterns align closely with the product label. Shifted clinical strategy from exploring new cancer types to strengthening market position and broadening labels for approved indications. Implemented operating expense discipline and R&D optimization, including a $90 million cost reduction in the LUNAR-2 trial, to accelerate the path to profitability. Updated full-year 2026 revenue guidance to $710 million to $725 million, reflecting confidence in sustained commercial momentum across the portfolio. Expects to reach full-year adjusted EBITDA breakeven in 2026, marking a significant milestone in the company's enterprise-wide focus on profitability. Anticipates an FDA decision on Optune Maia for brain metastases in Q4 2026, supported by recent NCCN guideline inclusions. Plans to expand Optune Pax into earlier stages of pancreatic cancer through new sponsored trials and potential industry partnerships. Assumes Japan will become the leading Optune Lua market as hospital-level contracting progresses in the coming quarters. Q2 revenue included $3 million in one-time benefits from improved approval rates in Germany and lower deductible resets in the U.S. Gross margin improved to 78%, aided by a $5 million tariff refund and manufacturing efficiencies, though management expects margins to normalize in the mid-70s. Received CE Mark for Optune Pax in locally advanced pancreatic cancer, with registration and physician certification already underway in Germany. Identified a $90 million savings opportunity by streamlining the LUNAR-2 trial protocol and reallocating resources to high-enrolling clinical sites. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management noted that approximately 50% of current prescribers are repeat users, with adoption occurring across both academic and community practices. The strategic focus for Q3 is to convert one-time 'trial' users into integrated, repeat prescribers to drive volume. Management is launching an IDE trial to explore safety and feasibility of combining TTFields with RAS inhibitors following their expected FDA approval. Preclinical data suggests TTFields may downregulate c-Myc, potentially creating a synergistic effect when used with KRAS inhibitors. The updated guidance accounts for $3 million in one-time items that occurred in Q2 and acknowledges the 'exceptional' alignment of growth factors during the period. Management emphasized a focus on the higher end of the range while remaining mindful of the high baseline set in the second quarter.

Novocure delivered record quarterly revenue and active patient growth, raised its full-year financial guidance and expanded the commercial reach of Optune Pax with European approval. Novocure (NASDAQ:NVCR) reported record second-quarter net revenue of $183.6 million, up 16% year over year. Global active patients receiving TTFields therapy increased 18% to 5,128 across all indications. The company raised its 2026 revenue guidance to $710 million-$725 million and improved its adjusted EBITDA outlook. Optune Pax received CE Mark approval for locally advanced pancreatic cancer, with Germany becoming the first European launch market. Upcoming FDA and clinical milestones in late 2026 could further expand the commercial opportunity for TTFields therapy. Novocure (NASDAQ:NVCR) reported second-quarter net revenue of $183.6 million, representing 16% growth from the prior year, driven primarily by higher global patient adoption of its Tumor Treating Fields (TTFields) therapy. The company ended the quarter with 5,128 active patients worldwide, an 18% increase year over year. Optune Gio remained the largest contributor with 4,636 active patients, while Optune Lua grew 51% to 207 active patients. Optune Pax also continued to build momentum following its U.S. launch. The company received 418 prescriptions during the quarter and reported 285 active U.S. patients at June 30. Commercial expansion continued beyond the United States after Optune Pax received CE Mark approval for the treatment of locally advanced pancreatic cancer. Germany is expected to become the first European market to launch the therapy. Financial performance also improved. Gross margin increased to 78% from 74% a year earlier, while adjusted EBITDA was positive at $10.8 million. Although Novocure reported a quarterly net loss of $15.7 million, loss per share improved as revenue growth continued to outpace operating expenses. The combination of accelerating patient growth, expanding indications and stronger profitability metrics suggests Novocure is progressing toward a broader commercial platform rather than relying solely on its original glioblastoma franchise. Management also increased its full-year outlook, raising expected 2026 revenue to $710 million-$725 million from the previous range of $690 million-$710 million. The adjusted EBITDA forecast improved to a range of break-even to $15 million, compared with prior guidance of a loss between $15 million and break-even. The guidance increase reflects confidence in continued commercial execution across Optune Gio, Optune Lua and Optune Pax. Additional pancreatic cancer launches in Europe could provide another source of revenue growth as reimbursement and market expansion progress. The company also strengthened its financial position, ending the quarter with $440.6 million in cash, cash equivalents and short-term investments. That liquidity may provide flexibility to support commercial launches, regulatory activities and ongoing clinical development without immediate financing needs. Investors will be watching the rollout of Optune Pax in Europe following the CE Mark approval, beginning with Germany. Another major catalyst is the expected fourth-quarter 2026 FDA decision on TTFields therapy for brain metastases from non-small cell lung cancer, which could further expand the addressable market. Completion of enrollment in the Phase 3 KEYNOTE D58 glioblastoma trial before year-end will also be an important milestone as Novocure continues to broaden the clinical evidence supporting its TTFields platform. Novocure stock price

Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications CE Mark received for Optune Pax® for the treatment of locally advanced pancreatic cancer, Germany first market to launch in EU More than 280 active patients on Optune Pax as of June 30, 2026 BAAR, Switzerland, July 23, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "This was our strongest quarter to date, with record net revenues and active patients on therapy," said Frank Leonard, CEO, Novocure. "We continue to launch our therapies in multiple markets allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability." Financial updates for the quarter ended June 30, 2026: Total net revenues for the quarter were $183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally. Gross margin for the quarter was 78% compared to 74% in the prior year. Cost of revenues in the quarter benefitted from a one-time $4.9 million tariff refund. Research, development and clinical study expenses for the quarter were $51.4 million, a decrease of 8% from the same period in 2025. This decrease was primarily driven by lower direct clinical trial expenses from completed trials. Sales and marketing expenses for the quarter were $61.7 million, an increase of 8% compared to the same period in 2025. This increase was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan. General and administrative expenses for the quarter were $39.9 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses. Net loss for the quarter was $15.7 million with loss per share of $0.13. Adjusted EBITDA* for the quarter was $10.8 million. Cash, cash equivalents and short-term investments were $440.6 million as of June 30, 2026. Operational updates for the quarter ended June 30, 2026: As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally. Optune Gio Optune Lua Optune Pax Quarterly updates and achievements: June 2026 2026 financial guidance: Novocure’s updated guidance for the full year 2026, as of July 23, 2026, is summarized below: Total net revenue: $710 million - $725 million (previous: $690 million - $710 million) Adjusted EBITDA*: $0 million - $15 million (previous: $(15) million - $0 million) This guidance assumes full-year mid-to-high single digit net revenue growth from Optune Gio, foreign exchange rates as of June 30, 2026 and consistent quarterly gross margin in the mid-70s percent. Anticipated clinical and regulatory milestones: Decision by the U.S. Food and Drug Administration on the premarket approval application for use of TTFields therapy for the treatment of brain metastases from non-small cell lung cancer (Q4 2026). Complete enrollment in Phase 3 KEYNOTE D58 clinical trial in newly diagnosed glioblastoma (Q4 2026). Conference call details Novocure will host a conference call and webcast to discuss second quarter 2026 financial results at 8:00 a.m. EDT today, Thursday, July 23, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter). *Non-GAAP Financial Measurements We measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation ("Adjusted EBITDA"). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. Indication and Important Safety Information for Optune Gio® What is Optune Gio® approved to treat? Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older. Newly diagnosed GBM If you have newly diagnosed GBM, Optune Gio is used together with a chemotherapy called temozolomide (TMZ) if: Your cancer is confirmed by your healthcare professional AND You have had surgery to remove as much of the tumor as possible Recurrent GBM If your tumor has come back, Optune Gio can be used alone as an alternative to standard medical therapy if: You have tried surgery and radiation and they did not work or are no longer working AND You have tried chemotherapy and your GBM has been confirmed by your healthcare professional Who should not use Optune Gio? Optune Gio is not for everyone. Talk to your doctor if you have: An implanted medical device (programmable shunt), skull defect (missing bone with no replacement), or bullet fragment. Optune Gio has not been tested in people with implanted electronic devices, which may cause the devices not to work properly, and Optune Gio has not been tested in people with skull defects or bullet fragments, which may cause Optune Gio not to work properly A known sensitivity to conductive hydrogels (the gel on the arrays placed on the scalp like the ones used on EKGs). When Optune Gio comes into contact with the skin, it may cause more redness and itching or may rarely cause a life-threatening allergic reaction Do not use Optune Gio if you are pregnant or are planning to become pregnant. It is not known if Optune Gio is safe or effective during pregnancy. What should I know before using Optune Gio? Optune Gio should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Gio. Do not use any parts that did not come with the Optune Gio Treatment Kit sent to you by Novocure or given to you by your doctor Do not get the device or transducer arrays wet If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune Gio treatment What are the possible side effects of Optune Gio? Most common side effects of Optune Gio when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression. The most common side effects when using Optune Gio alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers. Talk to your doctor if you have any of these side effects or questions. Please visit OptuneGio.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Indication and Important Safety Information for Optune Lua® What is Optune Lua® approved to treat? Optune Lua is a wearable, portable, FDA-approved device used together with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel. It is indicated for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. Who should not use Optune Lua? Optune Lua for mNSCLC is not for everyone. Talk to your doctor if you have: An electrical implant. Use of Optune Lua together with electrical implants has not been tested and may cause the implanted device not to work properly A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergies such as a fall in blood pressure and difficulty breathing Do not use Optune Lua if you are pregnant or are planning to become pregnant. It is not known if Optune Lua is safe or effective during pregnancy. What should I know before using Optune Lua? Optune Lua should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Lua. Do not use any parts that did not come with Optune Lua Treatment Kit sent to you by Novocure or given to you by your doctor Do not get the device or transducer arrays wet Please be aware that Optune Lua has a cord that plugs into an electrical socket. Be careful of tripping when it’s connected If you have an underlying serious skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Lua treatment. What are the possible side effects of Optune Lua? The most common side effects of Optune Lua when used together with certain immunotherapy and chemotherapy drugs were dermatitis, pain in the muscles, bones, or joints, fatigue, anemia, alopecia (hair loss), dyspnea, nausea, cough, diarrhea, anorexia, pruritus (itching), leukopenia, pneumonia, respiratory tract infection, localized edema (swelling), rash, pain, constipation, skin ulcers, hypokalemia (low potassium levels), hypoalbuminemia (low albumin levels), hyponatremia (low sodium levels), and dysphagia (difficulty swallowing). Other potential adverse effects associated with the use of Optune Lua include treatment related skin irritation, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown/skin ulcer. Talk to your doctor if you have any of these side effects or questions. Please visit OptuneLua.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. Indication and Important Safety Information for Optune Pax® What is Optune Pax® approved to treat? Optune Pax is an FDA-approved wearable therapeutic device, used together with gemcitabine and nab-paclitaxel (a chemotherapy combination). It is indicated for the treatment of adult patients with locally advanced pancreatic cancer. Who should not use Optune Pax? Optune Pax for locally advanced pancreatic cancer is not for everyone. Talk to your doctor if you have: An electrical implant. Use of Optune Pax together with electrical implants has not been tested and may cause the implanted device not to work properly. A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing Do not use Optune Pax if you are pregnant or are planning to become pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. It is not known if Optune Pax is safe or effective during pregnancy. What should I know before using Optune Pax? Optune Pax should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Pax. Do not use any parts that did not come with the Optune Pax Treatment Kit sent to you by Novocure or given to you by your doctor Do not get the device or transducer arrays wet Please be aware that Optune Pax has a cord that plugs into an electrical socket. Be careful of tripping when it's connected If you have an underlying skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Pax treatment What are the possible side effects of Optune Pax? The most common side effects of Optune Pax used together with chemotherapy drugs were low neutrophils, low red blood cell count, low platelet count, low white blood cell count, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, swelling, fever, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, liver enzyme increased, weight loss, low potassium level, low albumin level, high blood sugar, muscle pain, neuropathy peripheral (damage to the nerves outside the brain and spinal cord), taste disorder, dizziness, difficulty sleeping, shortness of breath, hair loss, skin-related disorders, and low blood pressure. Device-related skin adverse effects associated with the use of Optune Pax include skin inflammation, rash, itching, skin redness, skin irritation, skin infection, heavy sweating, and open sores. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays. Talk to your doctor if you have any of these side effects or have any questions. Please visit OptunePax.com for Instructions For Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions. View source version on businesswire.com: https://www.businesswire.com/news/home/20260723853009/en/ Contacts Investors: Adam [email protected] Media: Catherine [email protected]

This article first appeared on GuruFocus. Net Revenue: $184 million, an increase of 16% year-over-year. Optune Geo Active Patient Growth: 11% year-over-year. Optune Lua Contribution: $5.4 million. Optune Pax Contribution: $1.6 million. Gross Margin: 78%, up from 74% in Q2 2025. Research and Development Costs: $51 million, a decrease of 8% compared to Q2 2025. Sales and Marketing Expenses: $62 million, up 8% from Q2 2025. General and Administrative Costs: $40 million, a decrease of 9% from Q2 2025. Net Loss: $16 million, compared to $40 million in Q2 2025. Loss Per Share: $0.13. Adjusted EBITDA: $11 million, compared to negative $10 million in Q2 2025. Cash and Investment Balance: $441 million as of June 30, 2026. Warning! GuruFocus has detected 5 Warning Signs with NVCR. Is NVCR fairly valued? Test your thesis with our free DCF calculator. Release Date: July 23, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NovoCure Ltd (NASDAQ:NVCR) reported its strongest commercial quarter to date with record net revenues and active patients on therapy. The company saw an 11% year-over-year increase in active patients for Optune Geo, with significant growth in the U.S., Germany, Japan, and global markets. NovoCure Ltd (NASDAQ:NVCR) successfully launched Optune PACS, receiving 418 prescriptions and having 285 patients on therapy by the end of the quarter. The company received a CE mark for Optune Pax for treating locally advanced pancreatic cancer in Europe, expanding its market reach. NovoCure Ltd (NASDAQ:NVCR) achieved a positive adjusted EBITDA for the first time since 2024, indicating progress towards profitability. NovoCure Ltd (NASDAQ:NVCR) reported a net loss of $16 million for the quarter, although this was an improvement from the previous year. The company faces challenges in contracting with hospitals in Japan for Optune Lua, which could slow market penetration. There is uncertainty regarding the long-term sustainability of growth in the pancreatic cancer segment, as the company needs to increase repeat prescriptions. NovoCure Ltd (NASDAQ:NVCR) is not planning a registrational trial for TT Fields therapy with RAS inhibitors in metastatic pancreatic cancer, which may limit future market opportunities. The company is still working through reimbursement hurdles in Germany for Optune Pax, which could delay revenue realization. Q: Can you provide more details on the growth of the pancreatic cancer launch, specifically regarding the increase in strip volumes and active patients? Is this growth sustainable for the second half of the year? A: Francis Leonard, CEO, explained that the growth in pancreatic cancer is driven by both community and academic practices. About half of the prescriber base has become repeat prescribers, while the other half has initiated treatment once. The focus for the upcoming quarters is to increase the number of repeat prescribers and integrate Optune into routine clinical practice. Q: What gives you confidence in starting an IDE trial for TT Fields plus RAS inhibitors, and why is it not a registrational study? A: Francis Leonard, CEO, stated that the IDE trial will focus on safety and feasibility signals for TT Fields plus RAS inhibitors. The trial is not registrational because it aims to quickly gather safety data. Uri Weinberg, Chief Medical & Innovation Officer, added that preclinical results show promising signals when combining TT Fields with KRAS inhibitors, which supports the trial's initiation. Q: Can you discuss the prescribing patterns and patient acceptance for Optune PACS in pancreatic cancer? A: Francis Leonard, CEO, noted that about 50% of prescribers have used Optune PACS more than once. The focus is on increasing repeat prescriptions and integrating Optune into clinical practice. The company is seeing a mix of community and academic practices among high-volume sites, which is a positive development. Q: How should we think about the revenue guidance for the second half of the year, given the strong Q2 performance? A: Christoph Brackmann, CFO, explained that the revenue guidance was raised to $710 million to $725 million, representing 8% to 11% growth. The high end of the guidance aligns with Q2 results, which included $3 million in one-time items. The company aims to achieve outcomes towards the high end of the guidance range. Q: What are the expectations for Optune Lua in Japan, and how does the reimbursement process affect growth? A: Christoph Brackmann, CFO, mentioned that the launch in Japan has been strong, with expectations for sequential patient growth. However, the contracting process with hospitals is a gating item that the team needs to work through. The company is optimistic about continued growth in Japan. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in NovoCure Limited? Here are five stocks we like better. NovoCure posted record Q2 revenue of $184 million, up 16% year over year, with more than 5,000 patients on therapy. The company raised full-year revenue guidance to $710 million-$725 million and boosted adjusted EBITDA guidance to breakeven to $15 million. Optune Gio remained the main growth driver, ending the quarter with 4,636 active patients, up 11% from a year ago. Management also pointed to early contributions from Optune Pax and Optune Lua as additional revenue sources. Management signaled improving profitability through tighter expense control and cost cuts, including a redesigned LUNAR-2 trial expected to reduce spending by about $90 million. NovoCure reported adjusted EBITDA of $11 million in Q2 and said it is focused on reaching profitability in the coming years. NovoCure (NASDAQ:NVCR) reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance. Executive Chairman William Doyle said the quarter was NovoCure’s “strongest commercial quarter to date,” driven by record net revenues and active patients on therapy. The company reported net revenue of $184 million, up 16% year over year, and said more than 5,000 patients were on therapy across its products. → 3 Photonics Companies Making Quantum Tech Possible Chief Financial Officer Christoph Brackmann said the company now expects full-year revenue of $710 million to $725 million, representing 8% to 11% growth. That is up from the prior range of $690 million to $710 million. NovoCure also raised its full-year adjusted EBITDA outlook to a range of $0 to $15 million, with Brackmann saying the company now plans to reach adjusted EBITDA breakeven for the full year. Doyle said Optune Gio ended the quarter with 4,636 active patients on therapy, an 11% increase from the prior year. Growth in the U.S. was a key contributor, with active patients rising 8% year over year. Doyle attributed the U.S. performance to strategic and structural changes made in recent years to the company’s commercial operations. → Could Truth API Become Trump Media’s First Meaningful Revenue Driver? The company also reported double-digit year-over-year growth for Optune Gio in Germany, Japan and its global markets group. Brackmann said Optune Gio patient growth was the primary driver of the company’s revenue increase. He also cited contributions from newer products, including $5.4 million from Optune Lua and $1.6 million from Optune Pax. → AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off Management highlighted early progress for Optune Pax, the company’s therapy for locally advanced pancreatic cancer. Doyle said NovoCure received 418 prescriptions for Optune Pax during the quarter, and 285 patients were on therapy as of June 30. Doyle said the company has completed its early launch objectives, including engaging, training and supporting prescribers already familiar with the PANOVA-3 clinical data. He said adoption has been seen at both academic and community practices, and that feedback at the ASCO conference confirmed the PANOVA-3 survival data is viewed as important for patients with locally advanced pancreatic cancer. Chief Executive Officer Frank Leonard said during the question-and-answer session that about half of Optune Pax prescribers have already become repeat prescribers, while the other half have used the therapy once. He said NovoCure’s focus in the next phase of the launch is to move physicians from trying Optune Pax to integrating it into routine practice. NovoCure also received CE Mark approval for Optune Pax for adult patients with locally advanced pancreatic cancer of exocrine origin, used with gemcitabine and nab-paclitaxel in accordance with local guidelines. Doyle said the company has finalized labeling and registration in Germany and begun certifying prescribers. Optune Lua ended the quarter with 207 patients on therapy, including 64 in Japan as of June 30. Doyle said early launch signals in Japan are consistent with NovoCure’s view that Japanese clinical practice patterns align more closely with the product’s label than in other Optune Lua markets. The company received national reimbursement for Optune Lua in Japan in March and began certifying physicians shortly afterward. Doyle said additional contracting is required at each treatment site, and NovoCure expects Japan to become its leading Optune Lua market as more hospitals and prescribers are contracted. In response to an analyst question, Brackmann said the company expects sequential patient growth in Japan, though he noted that growth may become more difficult over time because the duration of therapy in the LUNAR clinical trial was about four months. Leonard said NovoCure is entering a new phase of clinical development. While the company’s historical strategy focused on establishing Tumor Treating Fields, or TTFields, in new cancer types, the current focus is on strengthening market position and broadening labels for approved therapies. Leonard said pancreatic cancer is the company’s near-term clinical priority. NovoCure is designing additional sponsored trials to support label expansion in locally advanced pancreatic cancer and earlier stages of disease where tumors may be resectable. He also said the company is in active negotiations with industry partners to explore TTFields in combination with RAS inhibitors or other innovative pancreatic cancer therapies in pilot trials. The company is also preparing to open an investigational device exemption trial for concurrent use of TTFields therapy and divarasib following its expected FDA approval. Leonard said the purpose of the trial is to generate safety and feasibility data quickly, and that NovoCure does not plan to open a registrational trial in metastatic pancreatic cancer at this time. In glioblastoma, Leonard said the KEYNOTE-D58 phase III trial remains on track to complete enrollment by year-end, with database lock and top-line results expected about two years later. The study is evaluating pembrolizumab added to TTFields therapy and maintenance chemotherapy. For non-small cell lung cancer, NovoCure is modifying its LUNAR-2 phase III trial to reduce costs and speed completion. Leonard said the company is reallocating clinical resources to higher-enrolling sites and amending the protocol to streamline primary endpoints, with an expected reduction in total LUNAR-2 spending of about $90 million. Those savings are expected to be allocated to pancreatic cancer programs. Brackmann said gross margin was 78% in the quarter, compared with 74% a year earlier, helped by a $5 million tariff refund, improved utilization and manufacturing efficiencies. He said quarterly gross margins are expected to remain in the mid-70% range through year-end 2026 as more Optune Pax patients begin therapy before broad reimbursement is established. Research and development costs fell 8% year over year to $51 million, while sales and marketing expenses rose 8% to $62 million due to the Optune Pax launch in the U.S. and Optune Lua launch in Japan. General and administrative costs declined 9% to $40 million, primarily because of lower share-based compensation. NovoCure reported a second-quarter net loss of $16 million, compared with a $40 million loss in the prior-year period. Loss per share was $0.13. Adjusted EBITDA was $11 million, compared with negative $10 million in the second quarter of 2025. The company ended the quarter with $441 million in cash and investments. “We are unambiguous in our enterprise-wide focus on reaching profitability in the coming years,” Brackmann said, citing revenue growth, expense management and cost-optimization projects such as the LUNAR-2 redesign. NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies. Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "NovoCure Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This drug developer is expected to post quarterly earnings of $0.86 per share in its upcoming report, which represents a year-over-year change of +14.7%. Revenues are expected to be $635 million, up 11.7% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Exelixis, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +6.31%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination indicates that Exelixis will most likely beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Exelixis would post earnings of $0.75 per share when it actually produced earnings of $0.87, delivering a surprise of +16.00%. Over the last four quarters, the company has beaten consensus EPS estimates four times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Exelixis appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. NovoCure (NVCR), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report loss per share of $0.3 for the quarter ended June 2026. This estimate points to a year-over-year change of +16.7%. Revenues for the quarter are expected to be $174.11 million, up 9.6% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for NovoCure has been revised 1.5% up to the current level. Nevertheless, the company now has an Earnings ESP of +0.83%, reflecting a higher Most Accurate Estimate. When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that NovoCure will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report NovoCure Limited (NVCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Wall Street expects a year-over-year increase in earnings on higher revenues when NovoCure (NVCR) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on July 23, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This oncology drug developer is expected to post quarterly loss of $0.30 per share in its upcoming report, which represents a year-over-year change of +16.7%. Revenues are expected to be $174.11 million, up 9.6% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 1.45% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For NovoCure, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.83%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that NovoCure will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that NovoCure would post a loss of$0.4 per share when it actually produced a loss of -$0.62, delivering a surprise of -55.00%. Over the last four quarters, the company has beaten consensus EPS estimates three times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. NovoCure doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NovoCure Limited (NVCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

BAAR, Switzerland, July 01, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, investor.novocure.com, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and X (Twitter). Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 26, 2026, and subsequent flings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion. View source version on businesswire.com: https://www.businesswire.com/news/home/20260701095256/en/ Contacts Investors:Adam [email protected] Media:Catherine [email protected]

Shareholders will be ecstatic, with their stake up 33% over the past week following NovoCure Limited's (NASDAQ:NVCR) latest quarterly results. Revenues of US$174m beat expectations by a respectable 3.7%, although statutory losses per share increased. NovoCure lost US$0.62, which was 21% more than what the analysts had included in their models. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the most recent consensus for NovoCure from seven analysts is for revenues of US$698.9m in 2026. If met, it would imply a modest 3.6% increase on its revenue over the past 12 months. Losses are expected to increase slightly, to US$1.57 per share. Before this latest report, the consensus had been expecting revenues of US$694.7m and US$1.54 per share in losses. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a pronounced increase to its losses per share forecasts. Check out our latest analysis for NovoCure The consensus price target held steady at US$25.21, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic NovoCure analyst has a price target of US$48.00 per share, while the most pessimistic values it at US$13.50. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We can infer from the latest estimates that forecasts expect a continuation of NovoCure'shistorical trends, as the 4.9% annualised revenue growth to the end of 2026 is roughly in line with the 4.5% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 7.9% per year. So it's pretty clear that NovoCure is expected to grow slower than similar companies in the same industry. The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at NovoCure. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that NovoCure's revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$25.21, with the latest estimates not enough to have an impact on their price targets. Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple NovoCure analysts - going out to 2028, and you can see them free on our platform here. You still need to take note of risks, for example - NovoCure has 2 warning signs we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.